Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

Kevin B. Kim*, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, Rene Gonzalez, Patrick A. Ott, Georgina V. Long, Olivia S. Gardner, Daniele Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

344 Citations (Scopus)

Fingerprint Dive into the research topics of 'Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences